Prevalence of Iodine-induced Hyperthyroidism after Administration of Iodinated Contrast during Radiographic Procedures: A Systematic Review and Meta-analysis of the Literature

Sandrina Bervini, MD¹, Sven Trelle, MD², Peter Kopp, MD³, Christoph Stettler, MD⁴, Roman Trepp, MD⁴

¹Department of Internal Medicine, Hospital Center, 2502 Biel, Switzerland.

Sandrina.Bervini@szb-chb.ch

²Clinical Trial Unit (CTU), University of Bern, 3000 Bern, Switzerland,

Sven.Trelle@ctu.unibe.ch

³Division of Endocrinology, Diabetology and Metabolism, University Hospital of Lausanne and University of Lausanne, 1011 Lausanne, Switzerland, Peter.Kopp@chuv.ch

⁴Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism (UDEM), Inselspital, Bern University Hospital, 3010 Bern, Switzerland, Christoph.Stettler@insel.ch, Roman.Trepp@insel.ch

Running title: Hyperthyroidism after ICM Administration

Keywords: Iodine-induced hyperthyroidism, IIH, iodinated contrast media, ICM, radiographic procedures

Abstract

Background: Iodine-induced hyperthyroidism (IIH) was a common issue in the early twentieth century after introduction of iodine supplementation in dietary salt. Currently, IIH is mostly encountered in Western countries as a consequence of radiographic procedures involving the administration of iodinated contrast media (ICM). However, little is known about the magnitude and clinical relevance of this issue. To assess the incidence of hyperthyroidism after ICM exposure, we performed a systematic review and meta-analysis of the literature.

Methods: MEDLINE, Embase and the Cochrane Library were systematically searched for studies published between 1946 and May 2018. Studies were considered eligible if they investigated the association between hyperthyroidism and iodinated contrast. Data on study design, baseline characteristics and outcomes were extracted independently by two reviewers.

Results: Thirty out of 1,493 retrieved studies were included in the analysis. The time endpoint to assess thyroid hormone levels after ICM exposure varied between 1-541 days among studies, with most studies having a time endpoint between 7-56 days. The overall estimated prevalence of overt hyperthyroidism after ICM exposure was extremely low (0.1%, 95% CI 0-0.6%), and did not change after adjustments for baseline thyroid function status (0.3% in euthyroid patients at baseline, 95% CI 0-1.7%). There were no cases with overt hyperthyroidism at 7 days after ICM exposure, and the incidence was very low at 30 days (0.2%, 95% CI 0-0.8%).

Conclusion: The incidence of IIH following ICM administration during radiographic procedures is extremely low.

Introduction

Iodine is an essential micronutrient in the synthesis of thyroid hormones. Its recommended daily allowance (RDA) by the World Health Organization (WHO) is 150 µg for non-pregnant adults; of this amount, about 80 µg are necessary to maintain adequate thyroid hormone production, the remainder accounts for fecal and urinary losses (1). Iodine is predominantly present in its organically bound form, but it occurs in many oxidation states including iodide (I^-), which is most commonly encountered as a component of iodized salt. Iodide is trapped and actively concentrated by the thyroid gland via the sodium-iodine symporter (NIS) and is essential for the synthesis of the thyroid hormones, T3 and T4. Exposure to high amounts of iodine causes an acute inhibitory effect on the synthesis of thyroid hormones. This phenomenon was first described in 1948 and is known as the “Wolff-Chaikoff effect”. It is normally followed by resumption of normal thyroid function within two days (2). An impairment of the acute Wolff-Chaikoff effect is typically observed in individuals with latent Graves’ disease or autonomous thyroid nodules (3). The incidence of focal autonomy increases with age and is higher in areas with iodine deficiency; these individuals may develop iodine-induced hyperthyroidism (IIH) when exposed to higher amounts of iodine because the increase in substrate results in the excessive synthesis and release of thyroid hormones by the autonomous tissue, a mechanism referred to as Jod-Basedow phenomenon (4). IIH was commonly observed shortly after introduction of iodine prophylaxis in deficient areas (e.g. up to 7% in Sweden after initiation of iodination programs), but its incidence has decreased during the last decades (5). However, IIH can still represent a medical issue secondary to the administration of high doses of iodine associated with the administration of iodinated contrast agents for radiographic procedures. It has, for example, been estimated that 80 million doses of iodinated contrast media (ICM) were administered worldwide in 2005 (6). Whereas patients with Graves’ disease and focal autonomy are thought to be at higher risk for developing hyperthyroidism after ICM administration, IIH has been described even in patients without prior thyroid dysfunction and with an apparently normal thyroid gland, although the pathophysiologic mechanism in this situation remains unclear (5).

In commonly used radiographic contrast media, the content of organic iodine ranges from 300 to 370 mg/ml, with higher contents in low-osmolar compared to high-osmolar agents. Low- and iso-osmolar agents are preferred in patients with impaired renal function, as the risk of contrast-induced nephropathy is reduced (1). The usual amount of ICM administered during a CT scan is 50-100 ml, equivalent to 15-37 g of iodine, which exceeds the RDA hundred thousand times (7). A fraction of the organoiodine is subject to deiodination, thus resulting in substrate for NIS and explaining the high urinary iodine concentration found in patients several weeks after ICM administration.

The prevalence of IIH varies widely between 0.05% and 5% among studies (8). This variability is explained by the heterogeneity of the study design of published studies and the variability in nutritional iodine intake. Moreover, most prospective studies only included small numbers of patients. As the number of radiographic procedures involving ICM grows steadily, it is of importance to get a more precise estimate of the prevalence, severity and clinical impact of IIH, and to identify which subjects may be at risk for IIH. For these reasons, we performed a systematic review and meta-analysis of the literature to investigate the prevalence of hyperthyroidism following administration of iodinated contrast agents for radiographic procedures.

Methods

A systematic review of published data according to the PRISMA statement for the conduct of meta-analyses (9) was performed to estimate the prevalence of IIH after the administration of ICM for radiographic procedures. Human subjects or the public were not involved in any way in our study.

Eligibility criteria

All original studies containing data about ICM-induced hyperthyroidism were eligible for inclusion. Exclusion criteria were case reports, letters, editorials and reviews, studies conducted on animals, subjects <18 years of age or on pregnant women, articles with only abstract available, duplications of articles, articles written in a language not known to the two reviewers (i.e. other than English, German, Italian and French), and articles on hyperthyroidism induced by other sources of iodine than iodinated radiographic contrast (i.e. iodine nutrient supplements, iodized salts, etc.).

Search strategy and study selection

We conducted a literature search in MEDLINE (**Appendix 1**), Embase and the Cochrane library for studies published between 1946 and May 2018. Search terms were “hyperthyroidism”, “thyrotoxicosis”, “thyroid (dys)function”, “thyroid autonomy”, “urinary iodine” AND “iodine-induced”, “iodinated contrast (media)”, “ICM”, “radiographic procedures/ contrast”, “contrast-induced”, “computed tomogram”, “CT scan” or “coronary angiography”. The search was done without language restriction, however we considered only studies written in languages known by the two reviewers.

After abstract screening and retrieval of potentially eligible studies, the full-text articles were assessed for eligibility. References of the retrieved articles were manually scanned to identify additional relevant publications. Duplicate studies were excluded, as were articles with no full text available. All articles were reviewed independently by two reviewers (S.B. and R.T.) and any disagreement was resolved by consensus.

Data extraction and management

Two reviewers (S.B. and R.T.) independently extracted data from included studies. Information was extracted and tabulated in a datasheet. Any disagreement was resolved by consensus. The data collected included time and location (including nutritional iodine supply status of the region) of the study, age, thyroid status of patients, relevant comorbidities, urinary iodine concentration, goiter and nodules (assessed by ultrasound), autonomy (assessed by scintigraphy) at baseline; type of radiographic procedure; type, administration route and amount of iodinated contrast media; assay used to measure thyroid hormones; and thyroid status as an endpoint of the study. If thyroid hormone levels were measured at multiple timepoints, the timepoint closest to 30 days was chosen as the endpoint, as this would be the time by which relevant overt hyperthyroidism is expected to be most prevalent. To avoid missing subjects with transient hyperthyroidism, we additionally looked into the prevalence of thyrotoxicosis at one week after ICM administration, whenever such data were available. Furthermore, data about the prevalence of hyperthyroidism in presumed high-risk subgroups (i.e. autonomy, subclinical hyperthyroidism, goiter) were extracted.

Data analysis

Individual study results are presented as percentage accompanied by Wilson score 95% confidence intervals. We pooled studies with a random effects model using the method of DerSimonian and Laird (10). To stabilize variances of individual studies, we used the Freeman-Tukey arcsine transformation. Between-study heterogeneity is quantified by the τ^2 and I^2 statistic. The approximate prediction interval was calculated based on the method proposed by Higgins and Thompson (11). All analyses were performed using Stata Release 15 (College Station, TX) and the metaprop command.

Quality assessment and risk of bias

For quality assessment, the following factors were considered:

1. Study design (study type, retrospective/ prospective)
2. Research question: whether the prevalence/incidence of IIH after administration of ICM was the primary endpoint of the study
3. Selection criteria:
 - a. whether the sampling method allowed for a representative sample of the source population
 - b. whether inclusion and exclusion criteria were appropriate (particularly with regards to thyroid status and pre-exposure to iodine)
4. Measurement of exposures and outcomes:
 - a. whether the assays used for thyroid hormone measurements can be regarded as valid (the following tests were considered to be valid: ELISA, immunoluminometric, and fluoroimmunoassays)
 - b. whether methods to ascertain participants characteristics were both valid and reliable (the following procedures were considered to be valid: for the assessment of thyroid size and structure: ultrasound or CT scan; to assess the presence of autonomy: radioiodine scan)
 - c. whether follow-up was long enough for the endpoint of interest
5. Appropriateness of analytical methods:
 - a. Whether the statistical method was appropriate for the outcome data
 - b. Whether >80% of the individuals had their samples analyzed

- c. Whether comparisons between individuals whose samples were analyzed and drop-outs (i.e. lost to follow-up) was presented, and whether they were similar

The methodological quality of the included studies was independently assessed by the two reviewers (S.B. and R.T.) in compliance with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) guidelines (12)(13) and disagreements were adjudicated. The overall level of evidence was rated as “high” when there was a high level of confidence that the pooled estimate lied close to the true population estimate, or as “very low” when the confidence was very low, with “low” and “moderate” being the in-between categories. According to the GRADE guidelines, the initial level of confidence in the estimates from observational studies was rated as “low”. The five GRADE domains (risk of bias, inconsistency, indirectness, imprecision and publication bias) were considered in downgrading confidence in the overall estimate; on the other hand, large effect, dose response gradient, and direction of plausible confounding were the criteria considered in upgrading the confidence in the estimates.

Results

Search results and study characteristics

The literature search yielded 1,493 articles (**Figure 1**). Of these, 38 were reviewed in full text and 30 articles met the final selection criteria and were included in the analysis. For one article (14), we only considered baseline characteristics, as endpoint thyroid hormone levels were not reported. Two studies were randomized controlled interventional trials, where the interventional arm of patients received prophylactic thyrostatic drugs prior to ICM administration (15, 16); for these studies, we considered only the patients in the observational arm. The iodine supply of the study region was reported in some of the articles. Other articles, however, did not contain any information about the local nutritional iodine intake; in this case, information was retrieved and reported according to the literature (Iodine global network, www.ign.org; (17)(18)(19)(20)). **Table 1** summarizes study design and characteristics of the studies included.

The time endpoint to assess thyroid hormone levels after ICM exposure varied between 1-541 days between studies. However, 28 out of 30 studies had a time endpoint between 7-56 days after ICM exposure to assess thyroid hormone levels.

Meta-Analysis

Twenty-nine studies had sufficient data on the prevalence of hyperthyroidism after ICM exposure (15, 16, 21–48). The pooled analyses included in **Figure 2** show the overall estimated prevalence of overt hyperthyroidism after ICM exposure in the 26 studies that reported it: the rate was extremely low (0.1%, 95% CI 0–0.6%). The 3 studies not included in the figure reported the overall rate of thyrotoxicosis, rather than only overt hyperthyroidism. **Figure 3** shows the prevalence of overt hyperthyroidism according to thyroid status at baseline [only in euthyroid patients versus patients with the full spectrum of thyroid function (euthyroidism, hypothyroidism, hyperthyroidism; “all patients”): the overall estimated prevalence was slightly higher in patients who were euthyroid at baseline (0.3%, 95% CI 0–1.7%) compared to “all patients” (0%, 95% CI 0–0.5%). The prevalence of subclinical hyperthyroidism at baseline was reported only in a small subset of studies and was very low; hence, no analysis could be performed on the prevalence of overt hyperthyroidism in patients with subclinical hyperthyroidism at baseline.

Subgroup analysis

To avoid possible bias, a subgroup analysis was performed after exclusion of the studies in which iopanoic acid and ipodate were used as iodinated contrast media, as these are thyrostatic agents that inhibit type 2 deiodinase, potentially leading to hypothyroidism. The prevalence of overt hyperthyroidism after exclusion of these studies did not change (0.1%, 95% CI 0–0.7%).

As there were major differences among studies regarding time endpoints at which thyroid function was assessed after ICM exposure, we performed a subgroup analysis for the prevalence of overt hyperthyroidism at one week and 30 days after ICM exposure (**Figure 4a, b**) because the risk of hyperthyroidism is expected to be higher between one of these timepoints. There were no events at one week and the prevalence was very low at 30 days (0.4%, 95% CI 0–0.12%).

Study quality

The methodological quality of the studies is reported according to the GRADE guidelines (**Table 2**). In the initial assessment, only one study (15) had a high level of evidence due to study type (randomized controlled trial). All other studies initially had a low level of evidence due to their observational study design. No study fulfilled the criteria for uprating

(i.e. large effect, dose response gradient, and direction of plausible confounding), mostly due to their small sample size. After adjusting for the quality of evidence according to GRADE domains (risk of bias, inconsistency, indirectness, imprecision, and publication bias), only one study (15) had a high level of evidence. Three studies (31, 36, 43) had a low level of evidence. All other studies had a very low level of evidence.

Discussion

To the best of our knowledge, this is the first meta-analysis that estimates the prevalence of overt hyperthyroidism after administration of ICM during radiographic procedures. The results demonstrate that the prevalence of IIH after ICM exposure is extremely low. They also suggest that the prevalence of IIH does not depend on the initial thyroid status. Although the number of patients with baseline subclinical hyperthyroidism was too small to perform a subgroup analysis, the few studies that specifically reported these data did not find the prevalence of overt hyperthyroidism to be higher in patients with baseline subclinical hyperthyroidism (15, 31).

Interestingly, two of the analyzed studies, both conducted in goitrous regions (Turin, Piedmont, and Wroclaw, Lower Silesia) found a considerably higher prevalence of IIH after ICM exposure (22, 43) compared to the other studies. Of note, the study by Bonelli et al. reported also higher rates of overt (0.37%) and subclinical (6.8%) hyperthyroidism at baseline. Potential explanations for these observations include that the population studied by Bonelli et al. was older (mean age 67 years), and that about a third (35%) had thyroid nodules and hence a potentially higher prevalence of focal autonomy, which could account for the higher rate of baseline hyperthyroidism. Moreover, only 20% of study patients were consumers of iodized salt; accordingly, median, but not mean urinary iodine concentration was borderline (100 µg/L). In contrast, the study by Hintze et al., which was also conducted in a low iodine intake area with a similar study design and number of patients, found lower baseline rates of subclinical (3.8%) and overt (0.14%) hyperthyroidism. This could be partly explained by the younger study population (mean age 55 years) and the lower prevalence of thyroid nodules (17%). When considering the type of ICM used, only two studies (43, 44) reported the use of iodixanol, an iso-osmolar contrast agent, whereas low- or high-osmolar agents were administered in all other studies. Interestingly, rates of IIH were higher in these two studies (10% in the study by

Bonelli et al. and 6,2% in the subpopulation of 16 patients reported by Jarvis et al.), with most of the patients having subclinical, and not overt, hyperthyroidism. Further studies are needed to investigate whether the use of iso-osmolar contrast media could be associated with higher rates of IIH.

The second study with a higher rate of IIH is the study by Skórkowska et al. (22). In that study patient age was similar (mean 58 years) to most studies, but there was a considerably higher rate of patients presenting with thyroid nodules at baseline (37%), similar to the study population of Bonelli et al., which could, again, account for a higher rate of autonomy. This hypothesis is further supported by the relatively high iodine uptake on baseline scintigraphy (mean 24%). Hence, the differences in hyperthyroidism rates both at baseline and after 4 weeks compared to other studies is likely explained by differences in the study population.

There were major differences in the type and amount of ICM, in the type of radiographic procedures, as well as in the time endpoint chosen to assess thyroid hormone levels. As the amount of organic iodine that is released from contrast agents clearly exceeds the RDA and hence may result in a Jod-Basedow phenomenon, it is apparent that the type of procedure and/or the amount of the administered ICM do not have a major influence on the prevalence of IIH.

Some of the studies might have been influenced by the use of iopanoic acid and ipodate, two radiographic agents that are well-known inhibitors of type 2 deiodinase and that have, therefore, also been used as thyrostatic agents in severe thyrotoxicosis. For this reason, we performed a subgroup analysis excluding studies where these two agents were used as contrast media; however, no difference was found in the prevalence of IIH, which remained extremely low.

There is considerable heterogeneity in the time endpoint chosen to assess thyroid function after ICM exposure among studies (1-541 days after exposure). In studies that reported multiple timepoints, we selected the timepoint closer to 30 days as the endpoint in order to compare them to other studies. A 30 day endpoint was the most commonly chosen timepoint in most of the selected studies, as the occurrence of overt hyperthyroidism after ICM exposure is expected around that time and urinary iodine excretion usually normalizes by 40 days (7, 49, 50). However, one may argue that some patients develop IIH at an

earlier timepoint and could therefore be missed. To address this question, we performed a subgroup analysis looking at the prevalence of IIH 7 days after ICM administration in the studies reporting data at this timepoint. However, there were again no differences in the prevalence of IIH, which remained very low.

Most of the included studies were performed more than 25 years ago, when radioimmunoassays (RIA) were commonly used for measuring thyroid hormone levels. Although these RIAs were, in part, less precise, we do not expect that this would introduce bias because clinically relevant thyroid dysfunction would have been detectable independently from the type of assay used.

An additional limitation is that most of the studies did not assess the presence of potential risk factors for the development of hyperthyroidism (i.e. goiter, focal autonomy of nodules), thereby introducing a potential selection bias. However, one of the biggest and qualitatively best studies included in the analysis presented here (36) did not identify any cases of IIH in patients with subclinical hyperthyroidism, goiter or autonomy at baseline. In this study, only 2 out of 788 patients developed IIH after ICM exposure, and neither of them had any risk factors at baseline.

According to GRADE criteria, we found an overall low quality of the analyzed studies. Only one study had a very high quality (15) and 3 studies were of low quality (31, 36, 43). All other studies had a very low quality, and most of them were performed more than 30 years ago on small patient samples and with very heterogeneous study designs. Moreover, since there has been considerable changes in the composition of ICM during the last 20 years, extrapolating data accrued in the 1980s to current clinical practice should be done with caution.

According to current recommendations, prophylactic treatment with thyrostatic drugs and/or perchlorate (where available) to avoid the risk of developing IIH may be considered for high-risk patients with suppressed TSH levels, especially in patients in whom adverse effects of thyrotoxicosis could compromise clinical outcomes, e.g. in patients with cardiac disease (51). However, the results presented here demonstrate that the prevalence of IIH after ICM exposure is very low. Therefore, it is questionable whether administration of a prophylactic regimen is indeed indicated in patients who are euthyroid or who have

subclinical hyperthyroid at baseline. Future studies should specifically address this question.

In summary, our results suggest that the prevalence of IIH following ICM administration during radiographic procedures is extremely low. Therefore, it is questionable whether prophylactic administration of thyrostatic drugs for the prevention of IIH is indicated, even in patients with possible risk factors at baseline.

Disclosures

The authors state that no competing financial interest exists.

Address of the corresponding Author

Sandrina Bervini, MD

Department of Internal Medicine

Hospital Center

2502 Biel, Switzerland

Sandrina.Bervini@szb-chb.ch

References

1. Lee SY, Rhee CM, Leung AM, Braverman LE, Brent GA, Pearce EN 2015 A review: Radiographic iodinated contrast media-induced thyroid dysfunction. *J Clin Endocrinol Metab* **100**:376–383.
2. WOLFF J, CHAIKOFF IL 1948 The inhibitory action of iodide upon organic binding of iodine by the normal thyroid gland. *J Biol Chem* **172**:855.
3. Stanbury JB, ERMans AE, Bourdoux P, Todd C, Oken E, Tonglet R, Vidor G, Braverman LE, Medeiros-Neto G 1998 Iodine-Induced Hyperthyroidism: Occurrence and Epidemiology. *Thyroid* **8**:83–100.
4. Selenkow HA, Utiger RD, Greer MA 1973 Jod-Basedow (or Jod-Coindet). *N Engl J Med*.
5. Roti E, Uberti ED 2001 Iodine Excess and Hyperthyroidism. *Thyroid* **11**:493–500.
6. Persson PB 2005 Contrast-induced nephropathy. *Eur Radiol* **15 Suppl 4**:D65-69.
7. Leung A, Braverman L 2015 Consequences Of Excess. *Nat Rev Endocrinol* **10**:136–142.
8. Hudzik B, Zubelewicz-Szkodzinska B 2014 Radiocontrast-induced thyroid dysfunction: Is it common and what should we do about it? *Clin Endocrinol (Oxf)* **80**:322–327.
9. Moher, D., Liberati, A., Tetzlaff, J., & Altman DG 2009 Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* **339**:b2535–b2535.
10. DerSimonian R, Laird N 1986 Meta-analysis in clinical trials. *Control Clin Trials*.
11. Higgins JPT, Thompson SG 2002 Quantifying heterogeneity in a meta-analysis. *Stat Med*.
12. Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., & Guyatt GH 2011 GRADE guidelines: Rating the quality of evidence. *J Clin Epidemiol* **64**:401–406.

13. Schünemann HJ, Cuello C, Akl EA, Mustafa RA, Meerpohl JJ, Thayer K, Morgan RL, Gartlehner G, Kunz R, Katikireddi SV, Sterne J, Higgins JP, Guyatt G 2018 GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. *J Clin Epidemiol*.
14. Marraccini P, Bianchi M, Bottoni A, Mazzarisi A, Coceani M, Molinaro S, Lorenzoni V, Landi P, Iervasi G 2013 Prevalence of thyroid dysfunction and effect of contrast medium on thyroid metabolism in cardiac patients undergoing coronary angiography. *Acta radiol* **54**:42–47.
15. Nolte W, Müller R, Siggelkow H, Emrich D, Höfner M 1996 Prophylactic application of thyrostatic drugs during excessive iodine exposure in euthyroid patients with thyroid autonomy: A randomized study. *Eur J Endocrinol* **134**:337–341.
16. Fritzsche H, Benzer W, Furlan W, Hammerle D, Langsteger W, Weiss P 1993 Prophylaxis of Iodine-Induced Thyrotoxicosis after Coronary Angiography. *Acta Med Austriaca* **20**:13–17.
17. Dalili S, Mohtasham-Amiri Z, Rezvani SM, Dadashi A, Medghalchi A, Hoseini S, Gholami-Nezhad H, Amirhaki A 2012 The Prevalence of Iodine Deficiency Disorder in Two Different Populations in Northern Province of Iran: A Comparison Using Different Indicators Recommended by WHO. *Acta Med Iran* **50**:822–826.
18. Leung AM, Braverman LE, Pearce EN 2012 History of U.S. iodine fortification and supplementation. *Nutrients* **4**:1740–1746.
19. Benedetti A, Friis J, Johnsen T, Bech K 1988 Journal of endocrinological investigation **11**.
20. WHO 2006 Vitamin and Mineral Nutrition Information System (VMNIS) The database on iodine deficiency includes data by country on goitre prevalence and / or urinary iodine concentration. World Health Organization Geneva.
21. Ozkan S, Oysu AS, Kayatas K, Demirtunc R, Eren M, Uslu H, Altuntas Y 2013 Thyroid functions after contrast agent administration for coronary angiography: a prospective observational study in euthyroid patients. *Anadolu Kardiyol Derg* **13**:363–369.

22. Skórkowska-Telichowska K, Kosińska J, Szymczak R, Tuchendler D, Tuchendler R, Telichowski A, Szajn G, Bolanowski M 2012 Comparison and assessment of thyroid morphology and function in inhabitants of Lower Silesia before and after administration of a single dose of iodine-containing contrast agent during cardiac intervention procedure. *Endokrynol Pol* **63**:294–299.
23. Monig H, Arendt T, Eggers S, Kloehn S, Folsch UR 1999 Iodine absorption in patients undergoing ERCP compared with coronary angiography. *Gastrointest Endosc* **50**:79–81.
24. Fassbender WJ, Vogel C, Doppl W, Stracke H, Bretzel RG, Klor HU 2001 Thyroid function, thyroid immunoglobulin status, and urinary iodine excretion after enteral contrast-agent administration by endoscopic retrograde cholangiopancreatography. *Endoscopy* **33**:245–252.
25. Gartner W, Weissel M 2004 Do Iodine-Containing Contrast Media Induce Clinically Relevant Changes in Thyroid Function Parameters of Euthyroid Patients Within the First Week? *Thyroid* **14**:521–524.
26. Lee SY, Chang DLF, He X, Pearce EN, Braverman LE, Leung AM 2015 Urinary Iodine Excretion and Serum Thyroid Function in Adults After Iodinated Contrast Administration. *Thyroid* **25**:471–477.
27. Reiner RG, Lawson MJ, Marshall J, Read TR, Beng CG, Davies GT, Tucker WG, Grant AK 1980 Thyroid, renal, and hepatic function tests following cholecystography with high-dose contrast agents. *Dig Dis Sci* **25**:379–383.
28. Conn JJ, Sebastian MJ, Deam D, Tam M, Martin FIR 1996 Prospective Study of the Effect of Nonionic Contrast Media on Thyroid Function. *Thyroid* **6**:107–110.
29. Fassbender WJ, Schlüter S, Stracke H, Bretzel RG, Waas W, Tillmanns H 2001 Schilddrüsenfunktion nach gabe jodhaltigen röntgenkontrastmittels bei koronarangiographie - Eine prospektive untersuchung euthyreoten patienten. *Z Kardiol* **90**:751–759.
30. Gorkem U, Kucukler FK, Kocabas R, Inal HA, Yilmaz N, Oruc AS, Gungor T 2016 The water-soluble iodinated contrast medium used for hysterosalpingography might increase the probability of development of subclinical thyroid diseases. *Int J Clin Exp Med* **9**:20008–20013.

31. Fricke E, Fricke H, Esdorn E, Kammeier A, Lindner O, Kleesiek K, Horstkotte D, Burchert W 2004 Scintigraphy for risk stratification of iodine-induced thyrotoxicosis in patients receiving contrast agent for coronary angiography: A prospective study of patients with low thyrotropin. *J Clin Endocrinol Metab* **89**:6092–6096.
32. Grainger RG, Pennington GW 1981 A study of the effect of sodium/meglumine ioxaglate (Hexabrix) on thyroid function. *Br J Radiol* **54**:768–772.
33. Grehn S, Steidle B, Seif FJ 1981 [Changes in thyroid function following iodine-containing contrast administration in patients in an endemic goitre area]. *Rofo* **135**:151–156.
34. Grubeck-Loebenstien B, Kronik G, Mossbacher H, Waldhausl W 1983 The effect of iodine containing contrast medium on thyroid function of patients undergoing coronary angiography. *Exp Clin Endocrinol* **81**:59–64.
35. Hanaghan J, Dhupelia D, Finucane J 1979 Thyroid hormones in serum: effects of X-ray contrast media. *Ir J Med Sci* **184**: 12–14.
36. Hintze G, Blombach O, Fink H, Burkhardt U, Kobberling J 1999 Risk of iodine-induced thyrotoxicosis after coronary angiography: an investigation in 788 unselected subjects. *Eur J Endocrinol* **140**:264–267.
37. Jaffiol C, Baldet L, Bada M, Vienne Y 1982 The influence on thyroid function of two iodine-containing radiological contrast media. *Br J Radiol* **55**:263–265.
38. Kaneshige T, Arata N, Harada S, Ohashi T, Sato S, Umehara N, Saito T, Saito H, Murashima A, Sago H 2015 Changes in serum iodine concentration, urinary iodine excretion and thyroid function after hysterosalpingography using an oil-soluble iodinated contrast medium (Lipiodol). *J Clin Endocrinol Metab* **100**:E469–E472.
39. Mann K, Rendl J, Busley R, Saller B, Seybold S, Hoermann R, Sauerbruch T, Borner W 1994 Systemic iodine absorption during endoscopic application of radiographic contrast agents for endoscopic retrograde cholangiopancreatography. *Eur J Endocrinol* **130**:498–501.
40. Rhee CM, Lynch KE, Zandi-nejad K, Elizabeth N, Alexander EK, Steven M 2013 Iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism in a community-based cohort. *Endocrinol Stud* **3**:27–30.

41. So S, Yamaguchi W, Tajima H, Nakayama T, Tamura N, Kanayama N, Tawara F 2017 The effect of oil and water-soluble contrast medium in hysterosalpingography on thyroid function. *Gynecol Endocrinol* **33**:682–685.
42. Breuel HP, Breuel C, Emrich D, Fischer P, Gilak A, Winkler C 1979 [Changes in thyroid function after application of iodinated contrast media to normal subjects]*Medizinische Klinik*.
43. Bonelli N, Rossetto R, Castagno D, Anselmino M, Vignolo F, Parasiliti Caprino M, Gaita F, Ghigo E, Garberoglio R, Grimaldi R, Maccario M 2018 Hyperthyroidism in patients with ischaemic heart disease after iodine load induced by coronary angiography: Long-term follow-up and influence of baseline thyroid functional status. *Clin Endocrinol (Oxf)* **88**:272–278.
44. Jarvis C, Simcox K, Tamatea JAU, McAnulty K, Meyer-Rochow GY, Conaglen J V., Elston MS 2016 A low incidence of iodine-induced hyperthyroidism following administration of iodinated contrast in an iodine-deficient region. *Clin Endocrinol (Oxf)* **84**:558–563.
45. Koroscil TM, Pelletier PR, Slauson JW, Hennessey J 1997 Short-term effects of coronary angiographic contrast agents on thyroid function. *Endocr Pract* **3**:219–221.
46. Nygaard B, Nygaard T, Jensen LI, Court-Payen M, Soe-Jensen P, Nielsen KG, Fugl M, Hansen JM 1998 Iohexol: Effects on uptake of radioactive iodine in the thyroid and on thyroid function. *Acad Radiol* **5**:409–414.
47. Rhee CM, Bhan I, Alexander EK, Brunelli SM 2012 Association between iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism. *Arch Intern Med* **172**:153–159.
48. Mekaru K, Kamiyama S, Masamoto H, Sakumoto K, Aoki Y 2008 Thyroid function after hysterosalpingography using an oil-soluble iodinated contrast medium. *Gynecol Endocrinol* **24**: 498-501.
49. Padovani RP, Kasamatsu TS, Nakabashi CD, Camacho CP, Andreoni DM, Malouf EZ, Marone MMS, Maciel RMB, Biscolla RPM 2012 One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy. *Thyroid* **22**:926–930.

50. Nimmons GL, Funk GF, Graham MM, Pagedar NA 2013 Urinary Iodine Excretion After Contrast Computed Tomography Scan. *JAMA Otolaryngol Neck Surg* **139**:479.
51. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA 2016 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. *Thyroid* **26**:1343–1421.

Table 1 Study design and characteristics of the 30 articles which met the final inclusion criteria.

<i>Author</i>	<i>Year</i>	<i>Design</i>	<i>Study type</i>	<i>Patients (n)</i>	<i>Mean age (years)</i>	<i>Iodine status</i>	<i>Baseline thyroid function</i>	<i>Radiologic procedure</i>	<i>Iodinated contrast used</i>	<i>Mean iodine load (g)</i>	<i>Endpoint (days)</i>
Nolte et al. ¹⁵	1996	RC T/cohort	P	17	63	deficie nt	SH	CA	Iodixanol	55.5	30
Fritzsche et al. ¹⁶	1993	Int/cohort	P	33	60	deficie nt	euthyroid	CA	Iopromide	64.7	28
Fricke et al. ²¹	2004	cohort	P	56	65	deficie nt	SH	CA	Iopromide	58.1	28
Breuel et al. ²²	1997	cohort	P	39	n.r.	deficie nt	euthyroid	CCG, PhG	Meglumin Ioglycanat, Methylglucaminsalz Troijodisophtalsäure-Methylamid	12.3	42
Bonelli et	2000	CS, L	P	810	66.4	deficie	all	CA	Iodixanol	82.7	30

al. ²³	1					nt						
	8											
Jarvis	2	coh	P	102	69.	suf	all	CT	Iodixanol, iohexol	30	28	
et	0	ort	S		5	fici						
al. ²⁴	1					ent						
	6											
Koros	1	coh	P	56	59	suf	all	CA	Sodium diatrizoat,	n.r.	7	
cil et	9	ort	S			fici			iohexol			
al. ²⁵	9					ent						
	7											
Nyga	1	coh	P	26	58	def	all	CT	Iohexol	30	30	
ard et	9	ort	S			icie						
al. ²⁶	9					nt						
	8											
Rhee	2	CC	R	361	46.	suf	euthyro	n.r.	n.r.	n.r.	252	
et	0		S		5	fici	id					
al. ²⁷	1					ent						
	2											
Meka	2	coh	R	214	34.	suf	euthyro	HSG	Lipiodol	4.8	51	
ru et	0	ort	S		5	fici	id					
al. ²⁸	0					ent						
	8											
Oezk	2	coh	P	101	59.	bar	euthyro	CA	Iopromide	n.r.	28	
an et	0	ort	S		5	ely	id					
al. ²⁹	1					suf						
	3					fici						
						ent						
Skork	2	coh	P	59	58.	bar	euthyro	CA	n.r.	60.7	30	
owsk	0	ort	S		7	ely	id					
a et	1					suf						

al. ³⁰	2						fici						
							ent						
Möni	1	coh	P	32	n.r	def	all	CA,	lopamidol, iopromide	n.r.	42		
g et	9	ort	S		.	icie		ERCP					
al. ³¹	9					nt							
	9												
Fassb	2	coh	P	102	60.	def	all	CA	lopromide	44.5	21		
ender	0	ort	S		1	icie							
et	0					nt							
al. ³²	1												
Gartn	2	coh	P	22	n.r	suf	euthyro	CA, CT	lopamidol, iopromide,	n.r.	7		
er et	0	ort	S		.	fici	id		iohexol, iodixanol				
al. ³³	0					ent							
	4												
Lee	2	coh	P	49	50.	suf	euthyro	CT	lopamidol	34.6	28		
et	0	ort	S		3	fici	id						
al. ³⁴	1					ent							
	5												
Reine	1	coh	P	53	53	bar	euthyro	CCG	lopamoic acid, ipodate	6	22		
r et	9	ort	S			ely	id						
al. ³⁵	8					suf							
	0					fici							
						ent							
Conn	1	coh	P	73	65.	bar	all	A, CA,	lopamidol, iopromide	n.r.	28		
et	9	ort	S		7	ely		CT,					
al. ³⁶	9					suf		IVP					
	6					fici							
						ent							
Fassb	2	coh	P	70	60.	def	euthyro	ERCP	lopromide	4.7	21		
ender	0	ort	S		5	icie	id						

et	0					nt						
al. ³⁷	1											
Gorke	2	coh	P	87	27.	bar	euthyro	HSG	Iohexol	n.r.	30	
m et	0	ort	S		8	ely	id					
al. ³⁸	1					suf						
	6					fici						
						ent						
Grain	1	coh	P	21	58.	suf	all	A	Sodium/meglumine	n.r.	0-56	
ger et	9	ort	S		6	fici			ioxaglate			
al. ³⁹	8					ent						
	1											
Greh	1	coh	P	119	n.r	def	all	CCG,	Ipodate, diatrizoat,	n.r.	28	
n et	9	ort	S		.	icie		IVP	ioglycamat			
al. ⁴⁰	8					nt						
	1											
Grub	1	coh	P	20	n.r	def	all	CA	Amidotricic acid	52.7	21	
eck-L.	9	ort	S		.	icie						
et	8					nt						
al. ⁴¹	3											
Hana	1	coh	P	31	41	suf	euthyro	CCG,	Iopanoic acid, sodium	n.r.	21	
ghan	9	ort	S			fici	id	IVP	diatrizoat			
et	7					ent						
al. ⁴²	9											
Hintz	1	coh	P	710	55	def	all	CA	Iopromide	n.r.	28	
e et	9	ort	S			icie						
al. ⁴³	9					nt						
	9											
Jaffiol	1	coh	P	20	30	suf	all	A	Sodium/meglumine	17.5	30	
et	9	ort	S			fici			ioxaglate and diatrizoat			
al. ⁴⁴	8					ent						

	2											
Kanes	2	coh	P	22	36.	suf	euthyro	HSG	Lipiodol		3.6	28
hige	0	ort	S		2	fici	id					
et	1					ent						
al. ⁴⁵	5											
Mann	1	coh	P	15	58	def	euthyro	ERCP	Iopamidol		7.3	28
et	9	ort	S			icie	id					
al. ⁴⁶	9					nt						
	4											
Rhee	2	coh	R	111	52.	suf	euthyro	n.r.	n.r.		n.r.	147-
et	0	ort	S	10	2	fici	id					541
al. ⁴⁷	1					ent						
	3											
So et	2	coh	P	73	34.	suf	euthyro	HSG	Lipiodol, Iotrolan		5	1-30
al. ⁴⁸	0	ort	S		3	fici	id					
	1					ent						
	7											
Marr	2	coh	R	175	69.	bar	all	CA	Iopamidol, Iopromide,		71.4	
accini	0	ort	S	2	2	ely			Iomeprol, Iobitridol,			
et	1					suf			Iodixanol			
al. ¹⁴	3					fici						
						ent						

Abbreviations

RCT: randomized control trial. Int: intervention study. CS: cohort study. CC: case control study. L: longitudinal study. PS: prospective study. RS: retrospective study. SH: subclinical hyperthyroidism. All: baseline thyroid status euthyroid, (subclinical) hypothyroid or subclinical hyperthyroid. CA: coronary angiography. CCG: cholecystography. PhG: phlebography. CT: computed tomogram. HSG: hysterosalpingography. ERCP: endoscopic retrograde cholangiopancreatography. A: angiography. IVP: intravenous pyelogram. NR: not reported.

Table 2 Methodological quality of the studies according to the GRADE guidelines.

<i>Author</i>	<i>Year</i>	<i>Initial quality</i>	<i>Risk of bias</i>	<i>Inconsistency</i>	<i>Indirectness</i>	<i>Imprecision</i>	<i>Publication bias</i>	<i>Quality of a body of evidence</i>
Nolte et al. ¹⁵	1996	++++	0	0	0	0	0	++++
Fritzsche et al. ¹⁶	1993	++	-2	0	0	-1	0	+
Fricke et al. ²¹	2004	++	0	0	0	0	0	++
Breuel et al. ²²	1979	++	-2	-1	-1	-1	0	+
Bonelli et al. ²³	2018	++	0	0	0	0	0	++
Jarvis et al. ²⁴	2016	++	0	0	-1	0	0	+
Koroscil et al. ²⁵	1997	++	-2	0	-1	0	0	+
Nygaard et al. ²⁶	1998	++	-2	0	-1	-1	0	+
Rhee et al. ²⁷	2012	++	-2	-1	-1	0	0	+
Mekaru et al. ²⁸	2008	++	-2	-1	-1	0	0	+
Oezkan et al. ²⁹	2013	++	-1	0	-1	0	0	+
Skorkowska et al. ³⁰	2012	++	-2	0	-1	0	0	+
Mönig et al. ³¹	1999	++	-1	0	-1	-1	0	+
Fassbende	20	++	-1	0	-1	0	0	+

r et al. ³²	01							
Gartner et al. ³³	20 04	++	-1	0	-1	-1	0	+
Lee et al. ³⁴	20 15	++	0	0	-1	-1	0	+
Reiner et al. ³⁵	19 80	++	-2	-1	-1	0	0	+
Conn et al. ³⁶	19 96	++	-2	0	-1	0	0	+
Fassbende r et al. ³⁷	20 01	++	-2	0	-1	0	0	+
Gorkem et al. ³⁸	20 16	++	-1	0	-1	0	0	+
Grainger et al. ³⁹	19 81	++	-2	-1	-1	-1	0	+
Grehn et al. ⁴⁰	19 81	++	-2	-1	0	0	0	+
Grubeck-L. et al. ⁴¹	19 83	++	-2	-1	-1	-1	0	+
Hanaghan et al. ⁴²	19 79	++	-2	-1	-1	-1	0	+
Hintze et al. ⁴³	19 99	++	0	0	0	0	0	++
Jaffiol et al. ⁴⁴	19 82	++	-1	-1	-1	-1	0	+
Kaneshige et al. ⁴⁵	20 15	++	0	0	-1	-1	0	+
Mann et al. ⁴⁶	19 94	++	0	0	-1	-1	0	+
Rhee et	20	++	-2	-1	-1	0	0	+

al. ⁴⁷	13							
So et al. ⁴⁸	20	++	-2	0	-1	0	0	+
	17							
Marraccini	20	++	-2	-1	-1	0	0	+
et al. ¹⁴	13							

Values meaning

Initial quality/ Quality of a body of evidence: +++, high. ++, moderate. +, low. +, very low.

Risk of bias/ inconsistency/ indirectness/ imprecision: 0, not serious. -1, serious. -2, very serious.

Publication bias: 0, not likely. -1, likely. -2, very likely.

Legends to the figures

Figure 1: Flow chart for the systematic review and meta-analysis

Figure 2: Overt hyperthyroidism at follow-up in All-Comers. Legend: Between-study heterogeneity $\tau^2=0.009$ - $I^2=45\%$. CI: confidence interval. PI: prediction interval.

Figure 3: Overt hyperthyroidism at follow-up in All-Comers by baseline status. Legend: Between-study heterogeneity within stratum euthyroid: $\tau^2=0.02$ - $I^2=56\%$; all: $\tau^2=0.01$ - $I^2=36\%$. Between-stratum heterogeneity: $p=0.82$. CI: confidence interval. PI: prediction interval.

Figure 4a: Overt hyperthyroidism at 1 week of follow-up in All-Comers. Legend: No pooled estimate provided because no cases were observed. CI: confidence interval.

Figure 4b: Overt hyperthyroidism at 30 days of follow-up in All-Comers. Legend: Between-study heterogeneity $\tau^2=0.01$, $I^2=47\%$. CI: confidence interval. PI: prediction interval.